Elizabeth Homans is a business-focused leader with an MBA from Harvard Business School. She was the CEO of Lyell Immunopharma, Inc. until December 2022. During her time at Lyell, she made significant contributions to the company's strategic goals. Notably, she...

Elizabeth Homans is a business-focused leader with an MBA from Harvard Business School. She was the CEO of Lyell Immunopharma, Inc. until December 2022. During her time at Lyell, she made significant contributions to the company's strategic goals. Notably, she experienced a considerable compensation structure during her tenure, with total earnings peaking at $18.6 million in 2021, primarily driven by stock options and bonuses. Homans also took home a severance package of $1.86 million upon her departure, which included eighteen months of salary and a full bonus for 2022. Despite a successful stint, her tenure ended with no public disputes with the company, reflecting a professional transition. Her career reflects strong leadership in the biotech sector and an inherent understanding of the business landscape, allowing her to adapt to the challenges faced by a growing company. Overall, her journey serves as a case study in navigating corporate leadership and the complexities of executive compensation in the biotechnology field.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Lyell Immunopharma, Inc. CEOs

L

Elizabeth Homans

Ex-CEO of Lyell Immunopharma, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

January 1, 1978 - 47 years ago

CEO of Lyell Immunopharma, Inc. for

1 year 2 months (Sep 2021 - Dec 2022)

Previous Experience

Former Chief Operating Officer at Lyell Immunopharma, Inc.

Rivals

Competitors/colleagues of Elizabeth Homans

Holdings

See how much did Elizabeth Homans make over time.

Elizabeth Homans held approximately 6.17 million shares of Lyell Immunopharma common stock during her time as CEO, a significant financial position reflecting her investment in the company’s growth. At peak moments, her holdings contributed to a substantial part of her...

Elizabeth Homans held approximately 6.17 million shares of Lyell Immunopharma common stock during her time as CEO, a significant financial position reflecting her investment in the company’s growth. At peak moments, her holdings contributed to a substantial part of her wealth, especially in 2021 when she received a favorable stock option grant worth around $17.65 million. Now, the situation reflects the fluctuations commonly seen in biotech stocks, where the potential for rapid growth exists, but so does risk. After her departure in December 2022, her wealth shifted as the company continues to navigate its position in the market without her leadership.

Loading...

Insider Trading

See recent insider trades of Elizabeth Homans.

No insider trades found for this CEO.

Compensation History

See how much did Elizabeth Homans make over time.

In her final year as CEO, Elizabeth Homans' total compensation was impressive, reaching around $1.86 million in 2022. This included her base salary, a sizable bonus, and a hefty severance payout due to her departure from the company. For instance, she received a $600,000 salary and a $360,000 bonus, highlighting her performance-based compensation structure. However, most interesting is the significant shift in her compensation package, showing from $18.6 million in 2021 down to nearly $2 million in 2022, reflecting her transition and the different challenges faced by the company. Understanding her compensation, it becomes clear that her leadership came with high financial stakes, typical in the fast-paced biotech sector.

Year

2022

Total Compensation

$1.86M

Salary

$600.00K

Board Justification

The compensation philosophy is designed to attract and retain talented individuals who possess the skills necessary to manage and grow the business, facilitate the achievement of strategic goals, and create long-term value for stockholders.

Bonus

$360.00K

Board Justification

In connection with her termination of employment, Ms. Homans was paid $360,000, equal to 100% of her target bonus amount for 2022, as part of her severance benefits.

Other

$900.00K

Board Justification

In addition to her salary and bonus, Ms. Homans received a cash payment of $900,000, which constitutes the equivalent of 18 months of her annual base salary in effect as of the date of her termination of employment.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2022 for Elizabeth Homans.

Performance Metrics

The performance metrics for determining the compensation included corporate goals related to advancing therapies and managing financial resources.

Other Lyell Immunopharma, Inc. CEOs

Here are other CEOs of Lyell Immunopharma, Inc.

Lynn Seely

CEO of Lyell Immunopharma, Inc.

December 2022 - Present